C-RFCNElixirgen Therapeutics
ZSCAN4, telomere elongation, mRNA
repairingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RFCN
C-RFCNC-RFCNZSCAN4, telomere elongation, mRNA
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Elixirgen Therapeutics states that controllable self-replicating RNA (c-srRNA) technology can be advanced into therapies for a broad spectrum of diseases, specifically including rare diseases, aging-related disorders, and cancer, reflecting a belief that next-generation RNA platforms can produce transformative treatments for patients in need.
SourceNo company mission, belief statement, or longevity theory is visible in the provided snapshot text; the visible text appears to be only the Wayback Machine navigation and capture metadata.
SourceElixirgen Therapeutics states that the ZSCAN4 gene has underused therapeutic potential and can be harnessed to reimagine cell therapy across rare diseases, aging-related disorders, and cancer. The company presents ZSCAN4 as a key genomic regulator that enhances genome stability, elongates telomeres, repairs chromosome abnormalities, and restores stem-cell developmental potency, and it frames telomere biology disorders as an initial proof-of-concept indication for therapies built from ex vivo ZSCAN4-treated autologous hematopoietic stem cells, with future expansion using a controllable self-replicating RNA platform.
Source